ADDvise receives allocation decision worth approximately SEK 44 million
ADDvise Group AB (publ)’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm-Gotland worth approximately SEK 44 million. The allocation decision consists of delivery of blood specimen collection equipment during a four-year period starting May 2022. The allocation decision is subject to an appeal time expiring 18 March 2022. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU